This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Are you holding a larger than normal allocation of cash these days? Seems like a lot of folks on Seeking Alpha are doing that if the site's contributors and commenters are representative. Have you given much thought to what you’re doing with that cash? Many of us roll it into their broker’s money market fund and don’t give it a lot of thought. Which is convenient and just fine if you’re using it as a brief holding between investments.
For the seventh week in a row, investors were net purchasers of fund assets (including those of conventional funds and ETFs) in general, adding a little more than $29.6 billion for Thomson Reuters Lipper's fund flows week ended June 6, 2018. However, the headline number was misleading. Despite upbeat economic reports and a market rally during the flows week, fund investors were net redeemers of equity funds (-$4.
IJR IJR IWM SCHP SHY SCHR
The U.S. stock market had a great week with all the major indices logging in more than 2% gains — the best week in two months. Notably, the Dow Jones posted seven consecutive days of gains, its largest winning streak since November. A combination of strong earnings, jump in oil prices and mild inflation has renewed confidence in the equity world. Oil prices surged following Trump’s decision to pull the United States out of the Iran nuclear deal.
VB FB QQQ GOOGL AAPL SHY EEM
For the third week in a row, investors were net purchasers of fund assets (including those of conventional funds and ETFs), taking in a little more than $8.2 billion. Despite market gains during the week, fund investors were net redeemers of equity funds (-$231 million) while being net purchasers of money market funds (+$8.2 billion), municipal bond funds (+$167 million), and taxable bond funds (+$86 million) for the fund-flows week ended May 9, 2018.
BRK.A IVV QQQ AAPL IVV SCHO IWM SHY EEM
The fixed income world gained immense investors' love in April amid persistent stock market volatility. This is especially true as bond ETFs accumulated $14.7 billion last month, representing the highest monthly inflows since October 2014, according to data from BlackRock (read: ETF Asset Report for April 2018: Bonds Top). iShares Short Treasury Bond ETF (SHV - Free Report) topped the list of asset creation, pulling in more than $2.
WFC WFCNP WFC.WS WFC.PRL WFC.PRJ FLOT WFC.PRT AGG WFC.PRR SHV WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW SHY WFC.PRV
The month of April was mixed with earnings showing promise and broader markets returning decent returns despite rising yields and trade tensions. Oil has been on an uptrend. Overall, SPDR S&P 500 ETF (SPY - Free Report) gained about 3.5% in a month’s time (as of Apr 27, 2018), SPDR Dow Jones Industrial Average ETF (DIA - Free Report) rose 2.9% while Nasdaq-100-bsed ETF PowerShares QQQ ETF (QQQ - Free Report) jumped 4.
AGG IVV IEMG DIA SPY IVV EFA FLOT SHY IEFA
U.S. Treasury yields have been somewhat seesawing as multiple factors are impacting the markets at the moment. Despite relatively strong economic fundamentals, trade war fears have made investors question their portfolio allocations and reallocate their assets to counter high volatility.
Thomson Reuters Lipper's fund asset groups (including both mutual funds and ETFs) suffered net outflows of $6.4 billion for the fund-flows week ended Wednesday, April 4. Equity funds (-$11.6 billion) were responsible for the overwhelming majority of the week's net outflows. It was the group's third straight week of negative net flows during which time its coffers shrank $35.6 billion. Taxable bond funds (+$3.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to SHY / iShares 1-3 Year Treasury Bond ETF on message board site Silicon Investor.
|Fishy statements on healthcare and other issues....||RAZF--Razorfish...Will this little fishy be a good catch??|
as of ET